002603.SZ
以岭药业
SZSE · Healthcare · C 制造业 · CN
CNY 15.84
−3.71%Year over year
Reported trailing growth
- Revenue
- +24.6%
- EBITDA
- —
- EBIT
- +353.0%
- EPS
- +294.9%
- Free cash flow
- +214.5%
- Operating cash flow
- +145.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -14.5%
- EBITDA
- -11.8%
- EBIT
- -16.9%
- Net income
- -18.3%
- EPS
- -18.3%
- Free cash flow
- -22.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026